TG Therapeutics Posts Wider Q1 Loss, Revenue Higher
08:07 AM EDT, 05/10/2021 (MT Newswires) -- TG Therapeutics (TGTX) on Monday reported a Q1 net loss of $0.69 per share, compared with a loss of $0.48 per share in the previous year.
Analysts polled by Capital IQ were expecting a net loss of $0.54 per share.
Revenue amounted to $793,000, up from $38,000 a year ago. Analysts were expecting revenue of $830,000.
The biopharmaceutical firm said that it plans to submit a biologic license application for ublituximab for the treatment of patients with relapsing forms of multiple sclerosis in Q3. It also plans to commence enrollment in ULTRA-V Phase 3 trial evaluating the triple combination of Ukoniq plus venetoclax in chronic lymphocytic leukemia.
Price: 40.00, Change: -0.20, Percent Change: -0.50